BRENTWOOD, Tenn.–(BUSINESS WIRE)–Tractor Supply Company (NASDAQ: TSCO), the largest rural lifestyle retailer in the United States, announced today the grand opening of its 11th distribution center, located in Nampa, Idaho. Serving as the strategic “Gateway to the Pacific Northwest,” the 865,000-square-foot state-of-the-art facility represents an investment of more than $200 million in Canyon County that will bring 500 full-time careers to the region. “As more people look to embrace the ‘Out H
Month: September 2026
NEW YORK–(BUSINESS WIRE)–Genius Sports Limited (“Genius Sports”) (NYSE:GENI) today announced that it will hold its 2026 Annual General Meeting of Shareholders on December 8, 2026. Details including the date and location of the meeting will be provided in a notice of meeting and related proxy materials in due course.About Genius SportsGenius Sports is a global leader in real-time sports data and technology, powering how live sports are captured, understood and experienced. As the official data
WINDSOR, Connecticut–(BUSINESS WIRE)–SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) hat heute auf seiner jährlichen Konferenz SS&C Deliver 2026 eine Reihe von Lösungen der nächsten Generation vorgestellt. Mehr als 1.100 Führungskräfte aus der Finanzdienstleistungs- und Gesundheitsbranche kamen in Orlando, Florida, zusammen, um zu erfahren, wie SS&C Geschäftsabläufe mithilfe KI-gestützter Dienste optimiert. Ein grundlegendes Technologiebündel, das die Bereiche Vermögensverwaltung,
WINDSOR, Conn.–(BUSINESS WIRE)–SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) oggi ha presentato una suite di soluzioni di nuova generazione alla sua conferenza annuale SS&C Deliver 2026. Più di 1.100 leader provenienti dai settori sanitario e dei servizi finanziari si sono riuniti a Orlando, Florida, per apprendere come SS&C stia ottimizzando i flussi di lavoro commerciali con servizi basati sull’AI. Una serie di tecnologie fondamentali che comprende i settori patrimoniale, pens
MIAMI–(BUSINESS WIRE)–duPont REGISTRY Group Announces Investment from Tom Cabrerizo Family Office and the Launch of Elferspot Events Platform
NEW YORK–(BUSINESS WIRE)–Principal Asset Management® et Longevity Partners ont annoncé aujourd’hui le lancement de REsponsible Asset Solutions (RAS), une nouvelle plateforme qui aide les propriétaires immobiliers institutionnels à identifier, adopter et mettre en œuvre des initiatives de décarbonation permettant d’améliorer la performance des bâtiments, de réduire la consommation d’énergie et d’accroître la valeur à long terme des actifs, tout en atteignant les objectifs de rendement des inve
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on its website.
Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of third quarter 2026 results, which are expected to be released on Tuesday, November 3, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and the Aide Memoire document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, and in our Quarterly Report on Form 10-Q for the second quarter of 2026, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Teva’s website at: https://ir.tevapharm.com/Events-and-Presentations.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva’s website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This Document and the presentation at the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com
FILADÉLFIA–(BUSINESS WIRE)–A Datavault AI Inc. (Nasdaq: DVLT) (“Datavault AI” ou a “Empresa”), uma empresa de Plataforma de Inteligência Artificial (“AIP”) que fornece tecnologias de monetização de dados, credenciamento e tokenização, anunciou hoje que seu conselho de administração (o “Conselho”) aprovou uma oferta de direitos de subscrição aos detentores de suas ações ordinárias (“Ações Ordinárias”) e de certos outros valores mobiliários da Datavault AI. A Moody Capital Solutions, Inc. (“Moo
NEW YORK–(BUSINESS WIRE)– #AIAgentSecuritySummit–Zenity was named a Market Shaper in Gartner’s inaugural Emerging Market Quadrant for AI Application Security, Startup Vendors.